KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Assets: 2010-2025

Historic Assets for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to $1.3 billion.

  • Pacira BioSciences' Assets fell 14.73% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 14.73%. This contributed to the annual value of $1.6 billion for FY2024, which is 1.33% down from last year.
  • Pacira BioSciences' Assets amounted to $1.3 billion in Q3 2025, which was down 15.59% from $1.5 billion recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Assets peaked at $2.1 billion during Q4 2021, and registered a low of $1.3 billion during Q1 2021.
  • For the 3-year period, Pacira BioSciences' Assets averaged around $1.5 billion, with its median value being $1.5 billion (2023).
  • Its Assets has fluctuated over the past 5 years, first surged by 62.83% in 2021, then declined by 19.46% in 2023.
  • Quarterly analysis of 5 years shows Pacira BioSciences' Assets stood at $2.1 billion in 2021, then fell by 18.99% to $1.7 billion in 2022, then fell by 6.35% to $1.6 billion in 2023, then decreased by 1.33% to $1.6 billion in 2024, then dropped by 14.73% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.6 billion during Q1 2025.